Ephedrine Injection

[24 August 2015]

Products Affected - Description

Ephedrine intravenous injection, Sandoz
50 mg/mL, 1 mL vial, 25 count (NDC 66758-0008-02)

Reason for the Shortage

  • Hospira discontinued ephedrine in March, 2011.
  • Sandoz discontinued ephedrine in summer 2015.

Available Products

Ephedrine intravenous injection, Akorn
50 mg/mL, 1 mL ampule, 10 count (NDC 17478-0515-00)

Ephedrine injection, Nexus Pharmaceuticals
50 mg/mL, 1 mL vial, 10 count (NDC 14789-0014-01)

Estimated Resupply Dates

Akorn and Nexus have product available.

Related Shortages


August 24, July 16, June 10 and 8, March 20, February 12, January 26, 2015; December 16, November 21, October 2 and 13, August 20, July 25, June 6 and 26, May 7 and 13, April 24, March 18, 2014, University of Utah, Drug Information Service. Copyright 2015, University of Utah, Drug Information Service.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.